Why SK Life Science Labs’ AACR 2026 data could put targeted protein degradation back in the oncology spotlight
What Doximity (NYSE: DOCS) CFO resignation means for governance, capital allocation, and investor confidence
Read More Pharma Industry News Relmada gains FDA support for dual Phase 3 study paths of NDV-01 in non-muscle invasive bladder cancer Find out how Relmada secured FDA alignment on dual Phase 3 paths for NDV-01 in NMIBC, opening two routes toward approval and a potential new bladder-sparing therapy. bySoujanya RaviNovember 4, 2025